[Pain in multiple sclerosis: prevalence, mechanisms, types and treatment]

Pedro E Bermejo1, Celia Oreja-Guevara, Exuperio Díez-Tejedor

  • 1UAM. Universidad Autonoma de Madrid. Hospital Universitario La Paz, 28046 Madrid, Espana. pedro.bermejo.v@gmail.com

Revista De Neurologia
|January 30, 2010
PubMed
Abstract

Insights

Pain significantly impacts multiple sclerosis (MS) patients, affecting up to 86%. Current treatments for MS pain are not specific, and its underlying causes remain unclear, necessitating further research.

Area of Science:

  • Neurology
  • Pain Medicine
  • Clinical Research

Background:

  • Pain is a common and impactful symptom in multiple sclerosis (MS).
  • Its prevalence and significance in MS patients are often underestimated.
  • Pain negatively affects daily activities and quality of life for individuals with MS.

Purpose of the Study:

  • To review the prevalence, types, mechanisms, and treatments of pain syndromes in multiple sclerosis.
  • To analyze the impact of pain on the quality of life for MS patients.
  • To identify current treatment strategies and knowledge gaps in managing MS-related pain.

Main Methods:

  • A non-systematic literature review was conducted.
  • Data on pain prevalence, types, associated factors, and treatments in MS were synthesized.
  • Classifications of MS pain syndromes were examined.

Main Results:

  • Pain affects a substantial percentage of MS patients, with prevalence estimates up to 86%.
  • Pain is linked to disease duration, disability, fatigue, depression, and advanced age.
  • Various pain types exist, including dysesthesias, trigeminal neuralgia, and headaches; however, treatments are not MS-specific.

Conclusions:

  • A high proportion of multiple sclerosis patients experience pain.
  • The pathophysiology of MS-related pain is not well understood.
  • There is a lack of specific treatments for MS pain, highlighting the need for further investigation.

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...